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Gliotransmission, a process involving active vesicular release of glutamate and other neurotransmitters by
astrocytes, is thought to play a critical role in many brain functions. A new paper by Nedergaard et al.
(2014) identifies an experimental flaw in these previous studies suggesting that astrocytes may not perform
active vesicular release after all.Over the past two decades, the role of glia
in the brain has undergone a renaissance
of sorts. These cells, once relegated as
mere passive bystanders of nervous
system development and function, have
garnered new respect as active contribu-
tors to brain physiology. Astrocytes, for
example, had long been thought to exist
for primarily homeostatic roles of clearing
excess synaptic neurotransmitters, main-
taining metabolic balance, and sustaining
the blood brain barrier. A large body of
work, however, soon identified several
predominant roles for astrocytes in active
neurodevelopmental and functional pro-
cesses. These come in multiple facets;
astrocytes are critically required for syn-
apse formation and function, neuronal
migration, synapse phagocytosis, and
even active waste clearance. But these
aspects of astrocytes function in brain
physiology have shared the spotlight
with another tantalizing theory, that astro-
cytes could actively modify synaptic ac-
tivity by the release of ‘‘gliotransmitters.’’
In the early 1990s, fundamental obser-
vations demonstrated that glutamate
could evoke rises in the intracellularcalcium (Ca2+) concentration in cultured
astrocytes and that the increase in Ca2+
concentration in astrocytes could evoke
a Ca2+ response in adjacent neurons
(Cornell-Bell et al., 1990; Nedergaard,
1994). This was an alluring finding,
because it indicated that astrocytes not
only receive information from neurons
but also that they could potentially feed
signals back to neuronal networks. This
idea quickly gained traction and gave
rise to the novel theory of the ‘‘tripartite’’
synapse. This new model proposed that
signal integration and transduction at syn-
apses should be considered in terms of
not only presynaptic and postsynaptic
terminals but also adjacent perisynaptic
astrocytic processes. Since the coining
of this term nearly two decades ago,
over 100 studies have been published
on the role of gliotransmission in normal
brain function. But over time, significant
dissent in the field has questioned the
paradigm of astroglial transmitter release
and modulation of synaptic transmission.
This topic has been reviewed extensively
from perspectives both in favor of astro-
cytic transmitter release (Araque et al.,2014; Halassa and Haydon, 2010) as
well as those to the contrary (Agulhon
et al., 2008; Nedergaard and Verkhratsky,
2012).
The main criticism against astrocytic
transmitter release has been concern
about the nonphysiological nature of
manyof theexperiments in support of glio-
transmition. Most of these studies have
been performed on cultured astrocytes,
raising the question of whether gliotrans-
mitter release actually occurs in vivo.
Perhaps the strongest in vivo evidence in
support of gliotransmissionwas thedevel-
opment of a transgenic mouse line in
which vesicular release could be specif-
ically inhibited in astrocytes. In these
mice, the formation of the SNARE com-
plex between vesicles and the plasma
membrane is inhibited by the expres-
sion of a dominant-negative domain
of the vesicle-associated membrane pro-
tein 2 (VAMP2) protein, which interferes
with endogenous VAMP2 expression and
thus prevents VAMP2-mediated mem-
brane fusion (Pascual et al., 2005). Most
importantly, the glial-fibrillary acidic pro-
tein (GFAP) promoter is used to drive
Neuron
Previewsdominant negative SNARE (dnSNARE)
expression selectively in astrocytes,
therefore restricting the inhibition of vesic-
ular release to the glial cohort of interest.
Exciting observations from these mice
support many of the in vitro findings of
gliotransmission. In fact, the elimination
of astrocytic transmitter exocytosis impli-
catedglia in processes thatwere tradition-
ally considered strictly neuronal, including
hippocampal LTP (Pascual et al., 2005),
sleep-wake cycles (Halassa et al., 2009),
and pain (Foley et al., 2011). Crucially,
however, all of these observations rely
on the premise that the specificity of the
dnSNAREmanipulation is restricted to as-
trocytes. This presumption is challenged
in a fundamental study published recently
in The Journal of Neuroscience, where
authors Fujita et al. (2014) propose that
many of these observations in dnSNARE
mice should be reexamined due to
leaky neuronal transgene expression.
The implications of this work raise critical
questions about a number of studies that
use the GFAP promoter to drive trans-
gene expression, extending beyond the
dnSNARE mice. Furthermore, hesitation
about the validity of thednSNARE findings
in astrocytes suggests that it may be
necessary to reconsider a large bulk of
evidence in favor of gliotransmission.
There were two compelling reasons for
the authors to assess the cellular speci-
ficity of the dnSNARE mice. First, ever
since the inception of using theGFAP pro-
moter for targeting transgene expres-
sion to astrocytes, suspicions soon arose
about the fidelity of the driver (Su et al.,
2004). These qualms were oftentimes
overlooked, and despite quiet apprehen-
sion, over 200 studies have since been
published using the GFAP promoter as
an astrocyte-specific driver. Second,
considering how integral VAMP2-medi-
ated exocytosis is to neuronal transmis-
sion, the authors worried that even a min-
imal amount of neuronal transgene
expression could have significant conse-
quences. Off-target expression of
dnSNARE in neurons could majorly
impact neural network activity, because
glutamatergic transmission critically de-
pends upon the formation of the SNARE
complex between synaptic vesicles and
the presynaptic membrane. In fact, dele-
tion of endogenous VAMP2 in neurons
reduces synaptic fusion events by over100-fold and is lethal immediately after
birth, suggesting that even aminor disrup-
tion of neuronal vesicular release has
the potential to suppress glutamatergic
transmission.
To achieve inducible and reversible
temporal control of dnSNARE transgene
expression, the dnSNARE mice utilize
a tetracycline-controlled transcriptional
activation system. In these mice, the
GFAP promoter drives expression of the
tetracycline transactivator (tTA), which
binds to the tetracycline operator (tetO)
directly upstream of a gene of interest
(in this case, dnSNARE). In the presence
of the tetracycline analog doxycycline
(Dox), tTA is inhibited, and tetO-mediated
transcription is suppressed. Conversely,
when Dox is removed, the tTA in
GFAP-expressing cells is free to activate
tetO-mediated dnSNARE expression. In
summary, the ‘‘On-Dox’’ condition be-
haves like wild-type, and ‘‘Off-Dox’’ trig-
gers transgene expression.
The authors first examined how inhibi-
tion of vesicular fusion in GFAP-express-
ing cells could alter overall cortical neural
activity. Surprisingly, they observed a dra-
matic reduction in EEG power 2 weeks
after discontinuing Dox treatment (thus
turning on dnSNARE transgene expres-
sion). This effect was reversible, as the
EEG power recovered completely after
the mice were again exposed to Dox.
This striking magnitude of EEG suppres-
sion (several fold) seemed too dramatic
to arise solely from the inhibition of glio-
transmission, which is purported to affect
synaptic transmission by 20%–30%.
Therefore, Fujita et al. (2014) next asked
if leaky neuronal transgene expression
might contribute to the observed pheno-
type. They harvested cortical tissue from
dnSNARE mice and utilized fluores-
cence-activated cell sorting (FACS) to
separate neurons from other brain cell
types and then looked for transgene
expression in the neuron versus non-
neuronal pools. Surprisingly, the authors
discovered significant dnSNARE tran-
scripts in the neuronal population. In addi-
tion to dnSNARE, these mice express two
reporter genes, LacZ and EGFP, under
tetO control. Both LacZ and EGFP
transcripts were also abundant in FACS
sorted neurons.
To validate their transcriptome findings
of leaky neuronal transgene expression,Neuron 84, Dethe authors used immunohistochemical
analysis to evaluate protein expression
in situ. Since EGFP is also under tetO con-
trol in dnSNARE mice, the authors utilized
EGFP expression as a proxy for the pres-
ence of dnSNARE in the adult cortex. As
expected, strong EGFP expression colo-
calized with GFAP-positive astrocytes,
but the authors also noted a low tomoder-
ate level of EGFP expression ubiquitously
across most NeuN-positive neurons. To
ensure that these results were not merely
an artifact of EGFP expression, Fujita
et al. (2014) also examined expression of
lacZ, a second tetO reporter in dnSNARE
mice. Identically to EGFP, lacZ expres-
sion was detectable in NeuN-positive
neurons in both cortex and hippocampus.
These findings demonstrate that the
GFAP promoter drives transgene expres-
sion in neurons in dnSNAREmice and that
direct suppression of neuronal vesicular
release may be responsible for the sup-
pression of EEG power in these mice
(summarized in Figure 1).
Is neuronal transgene expression via
the GFAP promoter a specific artifact of
dnSNARE mice? Considering the signifi-
cant implications of their findings, the
authors examined a second mouse line
where transgene expression is suppos-
edly restricted to astrocytes under the
GFAP driver. As in the dnSNARE mice,
this second independent strain contained
identical extensive neuronal expression of
the transgene in cortex and hippocam-
pus. Of note, however, both this and the
dnSNARE mice utilize the same inducible
tetracycline system. The authors report
that tetO- dnSNARE mice without GFAP-
tTA (these mice should have absolutely
no transgene expression) exhibit a basal
leakiness of expression throughout the
brain. Thus, it is possible to interpret that
neuronal transgene expression could be
a result of leaky tetO activity as opposed
to nonspecific GFAP promoter activation.
Previous studies of dnSNARE mice
have implicated adenosine as an integral
player by which astrocytes modulate
synaptic transmission (via the proposed
release of ATP that is immediately
degraded to adenosine) (Halassa et al.,
2009; Hines and Haydon, 2013; Nadjar
et al., 2013; Pascual et al., 2005). The
indications for adenosine as a causative
agent, however, have been largely indi-
rect. Here, Fujita et al. (2014) directlycember 17, 2014 ª2014 Elsevier Inc. 1113
Figure 1. Original and New Interpretations of dnSNARE Mice Phenotypes
(A) Schematic (A) depicts the interpretation of dnSNAREmice with the presumption that transgene expression is restricted to astrocytes. In the presence of Dox,
tetO-mediated dnSNARE expression is repressed in all cells. In the Off-Dox condition, however, astrocytic vesicular transmitter release is inhibited, and a sub-
sequent reduction in EEG power is observed. These observations suggest that astrocyte gliotransmitter release contributes to baseline neural activity. However,
the EEG power suppression in absence of Dox is more potent than it would be expected based on prior reports on gliotransmission.
(B) In scenario (B), new data demonstrate that suppression of EEG power is the result of direct inhibition of exocytosis of synaptic vesicles as a consequence of
leaky dnSNARE expression in neurons.
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adenosine in vivo using microdialysis to
examine whether glial (or neuronal) aden-
osine release was indeed affected by the
presence of dnSNARE. As expected,
adenosine levels were consistently higher
in dark phases when mice are awake and
active, in contrast to lower adenosine
levels in the light phase when mice
(nocturnal animals) are sleeping. These
diurnal fluctuations were present in both
wild-type and dnSNARE animals during
the ‘‘On-Dox’’ phase when transgene
expression should be off. Interestingly,
once Dox was removed, and astrocyte
vesicular fusion subsequently inhibited,
extracellular adenosine levels remained
almost identical to wild-type mice. This
was also true following episodes of sleep
deprivation, where previous reports
from dnSNARE mice had reported that
SNARE-dependent adenosine release1114 Neuron 84, December 17, 2014 ª2014from astrocytes contributed to accumula-
tion of sleep pressure. Of note, a number
of studies have utilized adenosine biosen-
sors to measure extracellular adenosine
in acute slices from dnSNARE mice and
have reached conclusions contrary to
those found by Fujita et al. (2014). The
authors point out that these biosensor
measurements detect adenosine concen-
trations in slice preparation studies that
are 6–200 times higher than reported
here in vivo. Fujita et al. (2014) suggest
that discrepancies between the ex vivo
biosensor recordings and in vivo micro-
dialysis technique may arise from the
ischemia and traumatic injury that occurs
during slice preparations.
Implications for Gliotransmission
Since its inception as a model by which
astrocytes modulate neuronal activity,
the theory of gliotransmission hasElsevier Inc.received a proportionate amount of
acceptance and criticism. Advocators of
the theory argue that repeated experi-
mental paradigms consistently converge
on the presence of active Ca2+-depen-
dent vesicular transmitter release from
astrocytes. Others, however, have con-
cerns about the experimental evidence
in support of the exocytic release of glio-
transmitters. In particular, they argue
that the majority of studies in favor of
gliotransmission have been performed
in vitro and raise concerns about the
physiological nature of the observations.
For example, although the Ca2+-depen-
dent release of glutamate from cultured
astrocytes has been demonstrated via a
number of methods, the mechanism of
such release is unclear. Any disruptions
of membrane permeability or anion chan-
nel opening can result in the efflux of cyto-
solic glutamate. In fact, when cultured
Neuron
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glutamate through volume-regulated
anion channels (Kimelberg et al., 1990),
and simple depolarization techniques
of astrocytes are sufficient to open hemi-
channels that cause cytoplasmic con-
tents (including ATP and glutamate) to
spill out of the cell. Further arguments
claim that glutamate concentrations
inside astrocytes are insufficiently low
due to the high concentration of the
enzyme glutamine synthetase, which
converts glutamate into glutamine—
although computational models argue
that functionally relevant levels of astro-
cyte glutamate may still be present (Ham-
ilton and Attwell, 2010). Finally, a myriad
of conflicting data exists regarding the
question of whether astrocytes contain
the necessary mechanical machinery for
Ca2+-dependent gliotransmitter release.
For example, transcriptome-level data
sets suggest that astrocytes express little
to no synaptotagmin proteins, which are
required for Ca2+-mediated vesicle fusion
(Zhang et al., 2014). The one exception
is the presence of synaptotagmin 11,
although it is still unclear whether this
protein is Ca2+ dependent and whether
it mediates kiss-and-run exocytosis as
opposed to full membrane fusion. Finally,
although several electron microscopy
studies demonstrate that astrocytes may
contain vesicular compartments that
could be used for exocytic release, astro-
cytes lack structurally organized release
zones apposed to neuronal postsynaptic
densities.
A number of studies on cultured astro-
cytes provide provocative data in sup-
port of exocytic transmitter release. For
example, capacitance measurements
indicate that release of glutamate from
cultured astrocytes is accompanied by
an increase in membrane area, as would
be expected for exocytic events. But
one might argue that manipulation to
cultured astrocytes is distinct from what
occurs in vivo. It is possible that either
cultured astrocytes express different pro-
teins than those in situ that endow them
with the ability to release transmitters or,
conversely, that the manipulations to
cultured astrocytes required to induce
transmitter release are nonphysiological.
Alternatively, like the observations made
by Fujita et al. (2014) in vivo, one might
question whether measurements of gluta-mate release by astrocytes in vitro is
largely an artifact of small numbers of
contaminating neurons. Typical methods
for purifying astrocytes by proliferating
young cells in serum-containing media
generate cultures that include a signifi-
cant population of stem cells. Thus,
although neuronal contamination may
initially be absent in these cultures, a
small number of neurons may be present
several days later when performing exper-
imental assays. Interestingly, when Foo
et al. (2011) established a method for
directly purifying astrocytes from rodent
brains to >99% purity (without expanding
the population in culture), no evoked
glutamate release could be induced.
The creation of the dnSNARE mice
provided perhaps the most significant
response to criticisms about in vitro and
ex vivo experiments on astrocyte glio-
transmission. A number of groups quickly
utilized the dnSNARE mice to implicate
astrocyte-secreted molecules in various
brain functions, although interestingly,
almost all of these involved astrocyte
ATP release and not glutamate. In light
of the findings presented by Fujita et al.
(2014), however, it is with caution that
such observations implicating in vivo glio-
transmission should be endorsed. It is
possible that many of these findings may
in some part be attributable to nonspecific
inhibition of synaptic transmission in neu-
rons. And it is with this major caveat that
the evidence for gliotransmission should
be critically re-evaluated. It is important
to note that the term gliotransmission,
itself, may be a largely semantic source
of debate. Most would agree in the validity
of gliotransmission when the definition
is limited to the astrocytic secretion of
neuroactive molecules. It is the specific
Ca2+-dependent vesicular release mech-
anism commonly affiliated with gliotrans-
mission that has garnered such height-
ened scrutiny.
The findings by Fujita et al. (2014)
emphasize the necessity for careful anal-
ysis of cell specificity in a number of con-
ditional mouse models. It is likely that
neuronal expression of target genes may
be present in other adult transgenic lines
that rely on the GFAP promoter for astro-
cyte-specific expression. Of course, each
founder line will vary in leakiness depend-
ing upon the site of integration of the
GFAP promoter, and thus, cell specificityNeuron 84, Demay be more or less of an issue depend-
ing upon the particular transgenic line.
In any case, careful scrutiny should be
taken to ensure cell type specificity. In
conclusion, this work provides a valuable
reminder about the caveats of mouse
genetics and reinvigorates the debate
about gliotransmission. Above all else, it
is an exemplar of the scientific method—
continually challenging and attempting
to rebut our most exciting hypotheses.
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